

**State of Oklahoma  
Oklahoma Health Care Authority  
Botulinum Toxins Prior Authorization Form**

**BILLING INFORMATION**

**Member Name:** \_\_\_\_\_ **Date of Birth:** \_\_\_\_\_ **Weight:** \_\_\_\_\_  
**Member ID#:** \_\_\_\_\_ **HCPCS Code:** \_\_\_\_\_ **CPT Code:** \_\_\_\_\_  
**Dose:** \_\_\_\_\_ **Frequency:** \_\_\_\_\_ **Start Date:** \_\_\_\_\_  
**Provider Name:** \_\_\_\_\_ **Medical Specialty:** \_\_\_\_\_  
**OHCA Provider #:** \_\_\_\_\_ **Phone:** \_\_\_\_\_ **Fax:** \_\_\_\_\_

**TO BE COMPLETED BY PRESCRIBER**

**Diagnosis:** \_\_\_\_\_ (Diagnosis is required for all Botulinum Toxins)

**Chronic Migraine Diagnosis:** please complete the following section. (Only Botox® will be approved.)

1. What is the monthly frequency of migraines? \_\_\_\_\_ What is the average duration of migraines? \_\_\_\_\_ hrs.
2. Have medical conditions known to cause or exacerbate migraines been ruled out/treated? Yes \_\_\_\_\_ No \_\_\_\_\_
3. Is the member chronically taking medications or other substances (which may be contained in food or drink items) known to cause or exacerbate migraines such as caffeine, narcotics, NSAIDs, APAP, or decongestants, etc.?  
Yes \_\_\_\_\_ No \_\_\_\_\_
4. Has the member failed at least 3 different types of medications typically used for migraine prevention (antihypertensives, anti-convulsants, anti-depressants, etc.)? Please list:  
Medication \_\_\_\_\_ Date Span \_\_\_\_\_ Dosing \_\_\_\_\_  
Medication \_\_\_\_\_ Date Span \_\_\_\_\_ Dosing \_\_\_\_\_  
Medication \_\_\_\_\_ Date Span \_\_\_\_\_ Dosing \_\_\_\_\_
5. Has the member been evaluated by a neurologist for chronic migraine headaches within the past 6 months?  
Yes \_\_\_\_\_ No \_\_\_\_\_ If yes, please include name of neurologist recommending Botox® treatment \_\_\_\_\_
6. Does the member currently use tobacco? Yes \_\_\_\_\_ No \_\_\_\_\_

**Overactive Bladder Diagnosis:** please complete the following section. (Only Botox® will be approved.)

1. Number of urinary incontinence episode(s) per day while on medication? \_\_\_\_\_
2. Have urodynamic studies been performed? Yes \_\_\_\_\_ No \_\_\_\_\_ If yes, include date \_\_\_\_\_
3. Has member participated in behavioral therapy? Yes \_\_\_\_\_ No \_\_\_\_\_ If yes, please give length of therapy and reason for therapy failure? \_\_\_\_\_
4. Has member used at least three anti-muscarinic medications for the treatment of overactive bladder?  
Medication \_\_\_\_\_ Date Span \_\_\_\_\_ Dosing \_\_\_\_\_  
Medication \_\_\_\_\_ Date Span \_\_\_\_\_ Dosing \_\_\_\_\_  
Medication \_\_\_\_\_ Date Span \_\_\_\_\_ Dosing \_\_\_\_\_
5. Does the member or caregiver have the ability to catheterize? Yes \_\_\_\_\_ No \_\_\_\_\_

**Neurogenic Bladder Diagnosis:** please complete the following section. (Only Botox® will be approved.)

1. Have urodynamic studies been performed? Yes \_\_\_\_\_ No \_\_\_\_\_ If yes, include date \_\_\_\_\_
2. What is the specific underlying pathological urologic dysfunction (such as small bladder capacity <400 cc, high detrusor pressure, etc)? \_\_\_\_\_
3. Does member keep diary of fluid intake, voiding/catheterization times and amounts or number of diapers/pads used daily? Yes \_\_\_\_\_ No \_\_\_\_\_
4. Clinical reason for failure of anticholinergic medication therapy? \_\_\_\_\_
5. Does the member have physical and cognitive ability to self-catheterize or access to caregiver? Yes \_\_\_\_\_ No \_\_\_\_\_

**Prescriber Signature:** \_\_\_\_\_ **Date:** \_\_\_\_\_

Please do not send in chart notes. Specific information/documentation will be requested if necessary.

PLEASE PROVIDE THE INFORMATION REQUESTED AND RETURN TO:

University of Oklahoma College of Pharmacy  
Pharmacy Management Consultants  
Product Based Prior Authorization Unit

Fax: 1-800-224-4014  
Phone: 1-800-522-0114 Option 4

CONFIDENTIALITY NOTICE

*This document, including any attachments, contains information which is confidential or privileged. If you are not the intended recipient, be aware that any disclosure, copying, distribution, or use of the contents of this information is prohibited. If you have received this document in error, please notify the sender immediately by telephone to arrange for the return of the transmitted documents or to verify their destruction.*